Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures <i>NPM1/FLT3</i>-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model
Bing Z. Carter,
Po Yee Mak,
Wenjing Tao,
Lauren B. Ostermann,
Duncan H. Mak,
Baozhen Ke,
Peter Ordentlich,
Gerard M. McGeehan,
Michael Andreeff
Affiliations
Bing Z. Carter
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Po Yee Mak
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Wenjing Tao
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Lauren B. Ostermann
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Duncan H. Mak
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Baozhen Ke
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Peter Ordentlich
Syndax, Waltham, MA
Gerard M. McGeehan
Syndax, Waltham, MA
Michael Andreeff
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
